PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
February 19, 2026Clinical Cancer Research

Abstract PS1-13-17: Rna-based immune features associated with benefit from distinct microtubule inhibitor therapy for metastatic her2-negative breast cancer: a post hoc analysis of the calgb 40502 (alliance) phase iii randomized clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

EBE. K. BligeKBK. V. BallmanAMA. R. Michmerhuizen

Discussion

Loading...

Member takes

Overview

Post hoc analysis demonstrates immune features impact outcomes in HER2-negative breast cancer treated with microtubule inhibitors, suggesting subtype-specific insights.

Key Points

  • This analysis aims to explore the relationship between RNA-based immune features and clinical outcomes in patients with HER2-negative metastatic breast cancer treated with microtubule inhibitors.
  • Conducted post hoc analysis of CALGB 40502 phase III trial data with 799 patients.
  • Evaluated pre-treatment primary tumor samples for stromal tumor infiltrating lymphocytes (sTILs) and RNA sequencing.
  • Analyzed immune deconvolution estimates using five algorithms.
  • Assigned PAM50 molecular subtypes based on transcriptomic features.
  • Explored associations between sTILs and curated breast cancer gene expression signatures.
  • High sTILs were found to be enriched in the basal-like PAM50 subtype (p=1e-4).
  • High T-cell and B-cell immune signatures correlated with improved overall survival in triple-negative breast cancer (HR=0.50, p=0.01).
  • High RNA-based immune scores were linked to worse overall survival in multiple datasets.
  • T-cell signatures indicated poor outcomes in patients receiving nab-paclitaxel, particularly in HR+/HER2- metastatic breast cancer.

Cite This Study

Blige et al. (2026) studied this question.

synapsesocial.com/papers/6996a898ecb39a600b3ef7e7https://doi.org/10.1158/1557-3265.sabcs25-ps1-13-17
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PO1-15-10: Lower pre-treatment B-cell gene expression signatures correspond with improved overall survival with palbociclib + endocrine therapy in HR+/HER2- metastatic breast cancer: a biomarker analysis from the GEICAM/2013-02 PEARL trial2024
  2. 2Abstract PO3-14-06: Immunologic features and association with prognosis in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) treated with chemotherapy (CT) or CDK4/6-inhibitors (CDK4/6i) + endocrine therapy (ET)2024
  3. 3Abstract PO4-25-03: Comprehensive immune profiling reveals factors associated with neoadjuvant chemotherapy response in triple negative breast cancer2024
  4. 4Abstract PS2-07-15: Immune biomarkers of standard-of-care chemoimmunotherapy response and resistance in real-world patient population: TBCRC0612026
  5. 5Abstract CT235: RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 study of 1L bevacizumab + pemetrexed/paclitaxel ± atezolizumab in metastatic NSCLC2024